Literature DB >> 3179328

Effects of MK-733, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, on absorption and excretion of [3H]cholesterol in rabbits.

F Ishida1, A Sato, Y Iizuka, Y Sawasaki, A Aizawa, T Kamei.   

Abstract

Effects of MK-733 on the absorption and excretion of cholesterol in rabbits were examined using [3H]cholesterol. The animals were divided into six groups; three groups were fed a normal diet, and the other groups a cholesterol diet. MK-733 was administered orally as a single dose of 10 mg/kg on day 8, or multiple doses of 10 mg/kg once a day for 14 days. On the 8th day, [3H]cholesterol was given orally to each animal. In the groups fed a normal diet, single and consecutive administration of MK-733 did not affect the absorption and excretion of [3H]cholesterol. In the cholesterol-fed groups, however, single administration of MK-733 decreased the serum 3H radioactivity slightly, but did not affect the fecal excretion of [3H]cholesterol. However, the consecutive treatment with MK-733 clearly reduced the serum 3H radioactivity. The cumulative excretion of the fecal radioactivity of [3H]cholesterol in the MK-733 group (multiple) was higher than that in the control group. From these results, it is concluded that MK-733 inhibits the absorption of cholesterol from the gastrointestinal wall in cholesterol-fed rabbits.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3179328     DOI: 10.1016/0005-2760(88)90335-9

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  10 in total

1.  Effect of lovastatin on acyl-CoA: cholesterol O-acyltransferase (ACAT) activity and the basolateral-membrane secretion of newly synthesized lipids by CaCo-2 cells.

Authors:  N T Kam; E Albright; S Mathur; F J Field
Journal:  Biochem J       Date:  1990-12-01       Impact factor: 3.857

2.  Inhibition of cholesterol absorption by HMG-CoA reductase inhibitor.

Authors:  T A Miettinen
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.

Authors:  J P Desager; Y Horsmans
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

4.  Effects of long-term treatment with simvastatin on plasma lipids and lipoproteins in patients with primary hypercholesterolemia.

Authors:  J Thiery; C Creutzfeldt; W Creutzfeldt; A K Walli; D Seidel
Journal:  Klin Wochenschr       Date:  1990-08-17

Review 5.  Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia.

Authors:  P A Todd; K L Goa
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

6.  Comparison of the effect of six compactin-related compounds on cholesterol synthesis in five human cell types.

Authors:  D D Sviridov; A Endo; V S Repin; V N Smirnov
Journal:  Lipids       Date:  1990-11       Impact factor: 1.880

Review 7.  Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia.

Authors:  G L Plosker; D McTavish
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

8.  Effects of lovastatin and dietary cholesterol on sterol homeostasis in healthy human subjects.

Authors:  W C Duane
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

9.  The effects of simvastatin and cholestyramine, alone and in combination, on hepatic cholesterol metabolism in the male rat. off.

Authors:  J H Shand; D W West
Journal:  Lipids       Date:  1995-10       Impact factor: 1.880

10.  Metabolic fate of 2,2-dimethylbutyryl moiety of simvastatin in rats: identification of metabolites by gas chromatography/mass spectrometry.

Authors:  N Uchiyama; Y Kagami; Y Saito; S Abe; M Ohtawa; S Hata
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jul-Sep       Impact factor: 2.441

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.